California Gov. Gavin Newsom has announced a $50 million, 10-year contract with nonprofit drugmaker Civica Rx to produce the state's own line of affordable insulin, CalRx, according to reporting from NPR and other sources. Upon FDA approval, these insulins, which are expected to be interchangeable with popular brand-name insulins, will be priced at no more than $30 per 10ml vial and $55 for a box of five pre-filled pen cartridges, potentially saving out-of-pocket patients up to $4,000 per year. The move is part of California's broader CalRx initiative to manufacture generic drugs under the state's label and disrupt the pharmaceutical industry, with plans to produce generic naloxone next.

Summary

• Factbox: What is the Willow project in Alaska, and why do green activists oppose it? | Reuters